RNhale
Planegg
About RNhale
RNhale GmbH is a spin-off originating from the Ludwig-Maximilians-University Munich, aiming to revolutionize the pharmaceutical landscape by developing a unique platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder. This disruptive approach synergizes technological and pharmaceutical strategies to create a novel therapeutic formulation with significant advantages over common LNP-RNA delivery methods. The target is pulmonary diseases with vast addressable markets and undeniable medical needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $2.6M
- Funding stage: Seed
- Last round: Seed (Jan 2025)
- Website: rnhale.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/rnhale-89849 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.